A large-scale program for controlling high blood pressure in a California health care system could help pave the way for improving blood pressure control in the general population.
Cangrelor is a potent, rapid-acting, reversible intravenous platelet inhibitor that was tested for percutaneous coronary intervention (PCI) in three large, double-blind, randomised trials.
Each of chronic kidney disease (CKD) and anemia is a potential independent risk factor for cardiovascular disease (CVD); however, reduced kidney function, anemia, and its relationship have not been fully evaluated for the incidence of atrial fibrillation (AF).
The use of drug-eluting stents (DES) in women is more effective and safe than using bare-metal stents during long-term follow-up, according to a study released on Sept. 2 during the ESC Congress 2013 and simultaneously published in The Lancet.
Данный сайт и вся информация на нём предназначена для медицинских работников.
Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.